CERESPIR
CereSpir is a biotechnology company focused on immuno-neurology, developing novel therapeutics for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. They utilize a unique class of pharmacological agents called AICD inhibitors to combat neuroinflammation and neurodegeneration, aiming to create disease-modifying treatments. Their lead compounds, Itanapraced (CSP-1103) and CSP-1103, are in various stages of clinical development, with plans for Phase 3 trials. The company collaborates with leading neuroscience institutes and has a strong patent portfolio to support their innovative approach.
Industries
Nr. of Employees
small (1-50)
CERESPIR
41 Madison Avenue, 31st Floor, New York, NY 10010
Patents
Products
Itanapraced (CSP-1103)
An orally available, brain-penetrant small molecule in clinical development that inhibits AICD activity, modulates microglial function (increases phagocytosis, reduces pro-inflammatory cytokines), and has been evaluated in Phase 1/2 studies and multiple preclinical models.
Itanapraced (CSP-1103)
An orally available, brain-penetrant small molecule in clinical development that inhibits AICD activity, modulates microglial function (increases phagocytosis, reduces pro-inflammatory cytokines), and has been evaluated in Phase 1/2 studies and multiple preclinical models.
Services
Engagement with pharmaceutical companies and academic centers for co-development, licensing, or strategic partnerships to advance clinical-stage small-molecule programs.
Engagement with pharmaceutical companies and academic centers for co-development, licensing, or strategic partnerships to advance clinical-stage small-molecule programs.
Expertise Areas
- Immuno-neurology drug discovery
- Preclinical pharmacology and animal model testing
- Clinical trial management for CNS disorders
- Biomarker development and clinical biomarker analysis
Key Technologies
- AICD-targeting small-molecule inhibitors
- Transgenic LRRK2 animal models
- Traumatic brain injury (TBI) preclinical models
- Cerebrospinal fluid (CSF) biomarker assays (TNF-α, CD40L, total tau)
News & Updates
Daniel G. Chain, PhD, President and CEO of Cerespir, will speak on Alzheimer's and Cognitive Disorders.
Richard A. Margolin, MD, Vice President, Clinical Development of Cerespir, will speak on optimizing late-stage Alzheimer’s Disease trials.
CERESPIR INCORPORATED announced it has identified a possible link between COVID-19 induced brain inflammation and ARDS, and aims to test its compound itanapraced as a treatment.
Animal studies show itanapraced blocks neurotoxicity and expression of LRRK2, supporting its potential as a disease-modifying treatment for Parkinson’s disease.
CereSpir obtained a patent from USPTO covering the optimal synthetic route for manufacturing CSP-1103, ensuring exclusive rights until October 2031.
Daniel G. Chain, PhD, President and CEO of Cerespir, will speak on Alzheimer's and Cognitive Disorders.
Richard A. Margolin, MD, Vice President, Clinical Development of Cerespir, will speak on optimizing late-stage Alzheimer’s Disease trials.
CERESPIR INCORPORATED announced it has identified a possible link between COVID-19 induced brain inflammation and ARDS, and aims to test its compound itanapraced as a treatment.
Animal studies show itanapraced blocks neurotoxicity and expression of LRRK2, supporting its potential as a disease-modifying treatment for Parkinson’s disease.
CereSpir obtained a patent from USPTO covering the optimal synthetic route for manufacturing CSP-1103, ensuring exclusive rights until October 2031.